系统综述与荟萃分析:老年炎症性肠病患者使用生物制剂与感染或癌症风险
结果显示生物制剂治疗与严重感染和机会性感染风险增加相关,而任何感染和癌症风险无显著影响,但证据质量低至极低。
要点
- 老年IBD患者使用生物制剂与严重感染风险增加相关(RR 2.70,95%CI 1.56-4.66)。
- 机会性感染风险亦增加(RR 3.16,95%CI 1.09-9.20),但证据质量低。
- 任何感染和癌症风险未显示显著影响,需大样本前瞻性研究进一步评估。
核心结论
- 生物制剂可能增加老年IBD患者严重感染和机会性感染的风险。
- 任何感染和癌症风险未显著受影响,但证据质量低至极低。
研究设计与样本
- 纳入15项研究:1项随机试验事后分析、9项队列研究和5项病例对照研究。
- 研究对象为60岁以上IBD患者,比较暴露与未暴露生物制剂者的感染和癌症风险。
主要发现
- 严重感染随机效应汇总相对风险2.70(95%CI 1.56-4.66;7项研究;I2=57%)。
- 机会性感染汇总相对风险3.16(95%CI 1.09-9.20;4项研究;I2=73%)。
- 任何感染汇总相对风险1.67(95%CI 0.51-5.43;5项研究;I2=75%),无显著影响。
- 癌症汇总相对风险0.90(95%CI 0.64-1.26;9项研究;I2=0%),无显著影响。
- 证据质量采用GRADE评定为低至极低。
临床怎么用
- 对老年IBD患者处方生物制剂时,应充分评估严重感染和机会性感染风险。
- 治疗决策需权衡获益与风险,并加强感染监测。
局限性
- 纳入研究多为观察性设计,存在偏倚风险。
- 证据质量低至极低,对效应估计的置信度有限。
- 缺乏大型前瞻性研究评估长期安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Uncertainty exists concerning the risk of infection and cancer associated with biologic therapies in elderly patients with inflammatory bowel disease (IBD). AIMS: To identify, synthesise and critically appraise the available evidence on the topic. METHODS: We systematically searched Medline/PubMed, Embase and Scopus, through October 2019, and recent conference proceedings, to identify studies investigating the risk of serious infections, opportunistic infections, any infection and cancer in elderly IBD patients (>60 years) exposed to biologics as compared to those unexposed to biologics. Two reviewers independently extracted study data and assessed each study's risk of bias. We examined heterogeneity, and calculated summary effect estimates using fixed- and random effects models. Quality of evidence was determined with GRADE. RESULTS: We included 15 studies (one post hoc analysis of a randomised trial, nine cohort and five case-control studies). Elderly IBD patients treated with biologics were at increased risk of developing serious infections (random effects summary relative risk: 2.70, 95% CI: 1.56-4.66; seven studies; I2 = 57%) and opportunistic infections (3.16, 1.09-9.20; four studies; I2 = 73%). The occurrence of any infection (1.67, 0.51-5.43; five studies; I2 = 75%) and cancer (0.90, 0.64-1.26; nine studies; I2 = 0%) was not significantly affected. Nevertheless, our confidence in the effect estimates is rather limited; the quality of evidence is low to very low. CONCLUSIONS: Biologics are likely to increase the risk of serious and opportunistic infections in old IBD patients. Large prospective studies are needed to further assess the biologic treatments' long-term safety profile in this population.
引用
- Piovani D, Danese S, Peyrin-Biroulet L, et al. Systematic review with meta-analysis: biologics and risk of infection or cancer in elderly patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2020. PMID: 32170782. doi:10.1111/apt.15692
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。